Stopping Disease-modifying Therapy in Relapsing and Progressive Multiple Sclerosis
Overview
Affiliations
Purpose Of Review: To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed.
Recent Findings: A number of retrospective observational studies in aggregate indicate that stopping DMTs may be attempted in older individuals with stable disease. Prognostic factors have been identified informing about the risk of recurrence of disease activity after DMT discontinuation.
Summary: Several clinical scenarios provide a rationale to stop DMTs in people with MS. Cumulative evidence has been gathered recently allowing us to more precisely weigh the risks against the benefits. This information aids in the decision process.
MS treatment de-escalation: review and commentary.
Selmaj K, Hartung H, Mycko M, Selmaj I, Cross A J Neurol. 2024; 271(10):6426-6438.
PMID: 39093335 PMC: 11447123. DOI: 10.1007/s00415-024-12584-x.
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.
Gross R, Corboy J Curr Neurol Neurosci Rep. 2024; 24(9):341-353.
PMID: 38995483 DOI: 10.1007/s11910-024-01355-w.
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.
Fernandez O, Soelberg Sorensen P, Comi G, Vermersch P, Hartung H, Leocani L Front Immunol. 2024; 15:1379538.
PMID: 38646534 PMC: 11032020. DOI: 10.3389/fimmu.2024.1379538.
Prosperini L, Haggiag S, Ruggieri S, Tortorella C, Gasperini C CNS Drugs. 2023; 37(10):915-927.
PMID: 37740822 DOI: 10.1007/s40263-023-01038-z.
Impact of aging on treatment considerations for multiple sclerosis patients.
Macaron G, Larochelle C, Arbour N, Galmard M, Girard J, Prat A Front Neurol. 2023; 14:1197212.
PMID: 37483447 PMC: 10361071. DOI: 10.3389/fneur.2023.1197212.